Global Immunomodulators Market Size To Worth USD 382.21 Million By 2033 | CAGR Of 6.11%

Global Immunomodulators Market Size To Worth USD 382.21 Million By 2033 | CAGR Of 6.11%                                                  

According to a research report published by Spherical Insights & Consulting, the Global Immunomodulators Market Size is Expected to Grow from USD 211.27 Million in 2023 to USD 382.21 Million by 2033, at a CAGR of 6.11% during the forecast period 2023-2033. 

Browse key industry insights spread across 210 pages with 117 Market data tables and figures & charts from the report on the "Global Immunomodulators Market Size, Share, and COVID-19 Impact Analysis, By Product (Immunostimulants, Immunoadjuvants, and Immunosuppressants), By Application (Human Immunodeficiency Virus (HIV), Respiratory Diseases, and Oncology), By End-User (Specialty Clinics, Hospitals, Homecare, and Others), By Distribution Channel (Retail Pharmacy, Online Pharmacy, Hospital Pharmacy, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033." Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/immunomodulators-market

The immunomodulators market focuses on developing, producing, and distributing drugs for managing autoimmune diseases. These drugs stimulate or suppress the immune system, supporting the human body in various medical conditions. They are classified into three categories: immunoadjuvants, immunostimulants, and immunosuppressants. The rising prevalence of autoimmune diseases drives the need for immunomodulators for their management. The Indian Council of Medical Research and the Department of Science and Technology support research on immunomodulators, with the growth of the immunomodulators market accelerated by growing awareness and the biotechnology and pharmaceutical sectors. The immunomodulator market is growing due to chronic diseases like asthma, allergies, cancer, and multiple sclerosis. Factors include organ transplantation, early treatment for Crohn's disease, inflammatory bowel diseases, autoimmune diseases, and drug resistance. The geriatric population is favoring immunomodulators due to their higher disease risk. Monoclonal therapy is also gaining popularity for various diseases. Oncology research is revealing new targets and mechanisms for immunomodulation, leading to sustained market expansion. However, rising infection risk and side effects associated with immunomodulators may impede the growth of the market growth.

The immunostimulants segment held the largest share of 46.84% in 2023 and is predicted to grow at a significant CAGR during the predicted period.

Based on the product, the global immunomodulators market is categorized as immunostimulants, immunoadjuvants, and immunosuppressants. Among these, the immunostimulants segment held the largest share of 46.84% in 2023 and is predicted to grow at a significant CAGR during the predicted period. The growth of the segment is attributed to the geriatric population, targeted immunostimulant therapy, personalized medicines, and the increasing use of herbal immunostimulants. The International Agency for Research on Cancer reported 20 million new cancer cases and 9.7 million deaths in 2022.

The oncology segment accounted for the highest market share of 57.18% in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.

Based on the application, the global immunomodulators market is categorized as human immunodeficiency virus (HIV), respiratory diseases, and oncology. Among these, the oncology segment accounted for the highest market share of 57.18% in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The segmental expansion in cancer treatment is driven by increased awareness, rising cancer cases, and the widespread use of immunomodulators, such as cytokines and immune check inhibitors.

The hospitals segment held the greatest share in 2023 and is predicted to grow at a substantial CAGR throughout the projected timeframe.

Based on the end-user, the global immunomodulators market is categorized into specialty clinics, hospitals, homecare, and others. Among these, the hospitals segment held the greatest share in 2023 and is predicted to grow at a substantial CAGR throughout the projected timeframe. The growth of this segment is attributed to frequent medical attention for chronic diseases, specialized services, insurance availability, advanced medical devices, preventive services, wellness programs, regular checkups, vaccinations, and physical rehabilitation centers for immune-mediated diseases.

The hospital pharmacy segment held the highest share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.

Based on the distribution channel, the global immunomodulators market is categorized into retail pharmacy, online pharmacy, hospital pharmacy, and others. Among these, the hospital pharmacy segment held the highest share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The growth of this segment is driven by collaborations between hospital pharmacies, healthcare professionals, and doctors, ensuring better patient outcomes, compounding medication, large immunomodulator stock availability, cost-effective medication management strategies, and better coordination with staff.

North America is expected to hold the greatest share of the global immunomodulators market over the forecast period.

North America is expected to hold the greatest share of the global immunomodulators market over the forecast period. North America's market dominance is driven by chronic illnesses, an aging population, and a preference for immunomodulatory medications. The region's sophisticated healthcare system and FDA-enforced safety requirements make rapid treatment adoption possible. The US holds the highest market share due to strong healthcare spending, favorable reimbursement rules, research focus, and early disease detection awareness.

Asia Pacific is predicted to hold the fastest-growing region of the global immunomodulators market throughout the estimated period. The Asia-Pacific immunomodulators market is thriving due to rising infectious diseases, cancers, and autoimmune disorders, along with the aging population's immune-related susceptibility. The region's healthcare infrastructure and investments are improving accessibility, while international pharmaceutical companies are producing new immunomodulatory drugs. Japan is expected to grow at the fastest pace.

Major key players in the global immunomodulators market are Merck and Co., Inc., Atox Bio, Horizon Therapeutics plc, Pfizer Inc., Squarex, Novartis AG, Amgen Inc., Reso Ther Pharma, Takeda Pharmaceutical Company Limited, BioRap Technologies Ltd., Johnson & Johnson Services, Inc., GlaxoSmithKline plc., ZERIA Pharmaceutical Co., Ltd., and others.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development

• In February 2025, ImmunityBio, Inc., a leading immunotherapy company, disclosed that the U.S. Food and Drug Administration (FDA) has authorized an expanded access program (EAP) to provide a vital alternative source of BCG, a standard-of-care medicine in the management of bladder cancer, to patients in the United States.

• In February 2025, Nexus Pharmaceuticals, LLC announced the U.S. Food and Drug Administration (FDA) approval of Tacrolimus Injection (5mg/ml). Tacrolimus injection is developed as an immunosuppressive drug that is used in various diseases, enhances the quality of life, and reduces the risk of organ rejection. It is available in the vial form.

• In January 2025, Charles River Laboratories International Inc. incorporated Akron Bio’s Closed System Solutions (CSS) liquid cytokines into its Cell Therapy Flex Platform for Process Development, enhancing closed-system processing, streamlining operations, minimizing risk, and improving process robustness.

• In July 2024, Hanmi Pharmaceutical Co., Ltd., announced the initiation of a phase-I clinical trial under the Food and Drug Administration (FDA) approval of the phase-I Investigational New Drug Application (IND) for its next-generation immunomodulatory anticancer drug (HM16390). These trials assessed the safety, tolerability, pharmacokinetics, and pharmacodynamic characteristics of HM16390 in patients with advanced solid tumors. HM16390 is a novel IL-2 variant and key regulator for immune function.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global immunomodulators market based on the below-mentioned segments:

Global Immunomodulators Market, By Product

• Immunostimulants
• Immunoadjuvants
• Immunosuppressants

Global Immunomodulators Market, By Application

• Human Immunodeficiency Virus (HIV)
• Respiratory Diseases
• Oncology

Global Immunomodulators Market, By End-User

• Specialty Clinics
• Hospitals
• Homecare
• Others

Global Immunomodulators Market, By Distribution Channel

• Retail Pharmacy
• Online Pharmacy
• Hospital Pharmacy
• Others

Global Immunomodulators Market, By Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

About the Spherical Insights & Consulting

Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.

Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements. 

CONTACT US:

For More Information on Your Target Market, Please Contact Us Below:    

Phone: +1 303 800 4326 (the U.S.)

Phone: +91 90289 24100 (APAC)

Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com

Contact Us: https://www.sphericalinsights.com/contact-us

Follow Us: LinkedIn | Facebook | Twitter